Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare, genetic epilepsy characterized by speech disorder (including a range of symptoms from dysarthria, speech dyspraxia, receptive and expressive language delay/regression and acquired aphasia to subtle impairments of conversational speech) and epilepsy (mostly focal and secondary generalized childhood-onset seizures, sometimes with aura). Mild to severe intellectual disability may also be observed.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for rolandic epilepsy-speech dyspraxia syndrome.
3 publications have been identified in PubMed for rolandic epilepsy-speech dyspraxia syndrome. Research spans Case Report / Case Series (67%) and Basic Science / Preclinical (33%).
Coburn RP (2026). [PMID: 41996995](https://pubmed.ncbi.nlm.nih.gov/41996995/). *Cortex*. [Case Report / Case Series]
Bertagnoli S (2025). [PMID: 40973146](https://pubmed.ncbi.nlm.nih.gov/40973146/). *Arch Clin Neuropsychol*. [Case Report / Case Series]
Anastasopoulou I (2025). [PMID: 40180575](https://pubmed.ncbi.nlm.nih.gov/40180575/). *J Neurosci*. [Basic Science / Preclinical]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 3:34 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center